Aurobindo Pharma USA Inc. recalls Pioglitazone Tablets USP, 45 mg, 500 count bottles, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ -- NDC
Recalled February 2, 2022 · FDA recall D-0450-2022 · Aurobindo Pharma USA
Hazard
Superpotent and Failed Tablet/Capsule Specifications · FDA Class II
Units
792 bottles
Sold at
Nationwide in the US
Description
Superpotent and Failed Tablet/Capsule Specifications
Product
Pioglitazone Tablets USP, 45 mg, 500 count bottles, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ -- NDC 57237-221-05
Manufacturer(s)
Aurobindo Pharma USA Inc.
Source: U.S. Food and Drug Administration. Official recall notice on fda.gov →